The Relationship Between IDH1 Mutation Status and Metabolic Imaging in Nonenhancing Supratentorial Diffuse Gliomas: A C-MET PET Study

Overview

Journal Mol Imaging

Publisher Sage Publications

Specialty Radiology

Date 2020 Jan 1

PMID 31889470

Citations 5

Authors

Nijiati Kudulaiti

Huiwei Zhang

Tianming Qiu

Junfeng Lu

Abudumijiti Aibaidula

Zhengwei Zhang

Yihui Guan

Dongxiao Zhuang

Affiliations

Soon will be listed here.

Abstract

Purpose: We evaluated the relationship between isocitrate dehydrogenase 1 (IDH1) mutation status and metabolic imaging in patients with nonenhancing supratentorial diffuse gliomas using C-methionine positron emission tomography (C-MET PET).

Materials And Methods: Between June 2012 and November 2017, we enrolled 86 (38 women and 48 men; mean age, 41.9 ± 13.1 years [range, 8-67 years]) patients with newly diagnosed supratentorial diffuse gliomas. All patients underwent preoperative C-MET PET. Tumor samples were obtained and immunohistochemically analyzed for IDH1 mutation status.

Results: The mutant and wild-type IDH1 diffuse gliomas had significantly different mean maximum standardized uptake value values (2.73 [95% confidence interval, CI: 2.32-3.16] vs 3.85 [95% CI: 3.22-4.51], respectively; = .004) and mean tumor-to-background ratio (1.90 [95% CI: 1.65-2.16] vs 2.59 [95% CI: 2.17-3.04], respectively; = .007).

Conclusions: C-methionine PET can noninvasively evaluate the IDH1 mutation status of patients with nonenhancing supratentorial diffuse gliomas.

Citing Articles

New insights into the cardio-renal benefits of SGLT2 inhibitors and the coordinated role of miR-30 family.

El Khayari A, Hakam S, Malka G, Rochette L, El Fatimy R Genes Dis. 2024; 11(6):101174.

PMID: 39224109 PMC: 11367061. DOI: 10.1016/j.gendis.2023.101174.

Glioma lateralization: Focus on the anatomical localization and the distribution of molecular alterations (Review).

Tuncel Cini N, Pennisi M, Genc S, Spandidos D, Falzone L, Mitsias P Oncol Rep. 2024; 52(4).

PMID: 39155859 PMC: 11358673. DOI: 10.3892/or.2024.8798.

Diagnostic accuracy of anti-3-[F]-FACBC PET/MRI in gliomas.

Karlberg A, Pedersen L, Vindstad B, Skjulsvik A, Johansen H, Solheim O Eur J Nucl Med Mol Imaging. 2023; 51(2):496-509.

PMID: 37776502 PMC: 10774221. DOI: 10.1007/s00259-023-06437-4.

Predictive IDH Genotyping Based on the Evaluation of Spatial Metabolic Heterogeneity by Compartmental Uptake Characteristics in Preoperative Glioma Using F-FET PET.

Lohmeier J, Radbruch H, Brenner W, Hamm B, Tietze A, Makowski M J Nucl Med. 2023; 64(11):1683-1689.

PMID: 37652542 PMC: 10626372. DOI: 10.2967/jnumed.123.265642.

Noninvasive differentiation of molecular subtypes of adult nonenhancing glioma using MRI perfusion and diffusion parameters.

Pruis I, Koene S, Van der Voort S, Incekara F, Vincent A, van den Bent M Neurooncol Adv. 2022; 4(1):vdac023.

PMID: 35300151 PMC: 8923005. DOI: 10.1093/noajnl/vdac023.

References

Kamson D . Hypometabolic gliomas on FET-PET-is there an inverted U-curve for survival?. Neuro Oncol. 2019; 21(10):1221-1222. PMC: 6784274. DOI: 10.1093/neuonc/noz122. View

Kawaguchi T, Sonoda Y, Shibahara I, Saito R, Kanamori M, Kumabe T . Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion. J Neurooncol. 2016; 129(3):505-514. DOI: 10.1007/s11060-016-2201-2. View

Shinozaki N, Uchino Y, Yoshikawa K, Matsutani T, Hasegawa A, Saeki N . Discrimination between low-grade oligodendrogliomas and diffuse astrocytoma with the aid of 11C-methionine positron emission tomography. J Neurosurg. 2011; 114(6):1640-7. DOI: 10.3171/2010.11.JNS10553. View

Matsuo M, Miwa K, Tanaka O, Shinoda J, Nishibori H, Tsuge Y . Impact of [11C]methionine positron emission tomography for target definition of glioblastoma multiforme in radiation therapy planning. Int J Radiat Oncol Biol Phys. 2010; 82(1):83-9. DOI: 10.1016/j.ijrobp.2010.09.020. View

Aibaidula A, Chan A, Shi Z, Li Y, Zhang R, Yang R . Adult IDH wild-type lower-grade gliomas should be further stratified. Neuro Oncol. 2017; 19(10):1327-1337. PMC: 5596181. DOI: 10.1093/neuonc/nox078. View

Eckel-Passow J, Lachance D, Molinaro A, Walsh K, Decker P, Sicotte H . Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. N Engl J Med. 2015; 372(26):2499-508. PMC: 4489704. DOI: 10.1056/NEJMoa1407279. View

Sadeghi N, Salmon I, Tang B, Denolin V, Levivier M, Wikler D . Correlation between dynamic susceptibility contrast perfusion MRI and methionine metabolism in brain gliomas: preliminary results. J Magn Reson Imaging. 2006; 24(5):989-94. DOI: 10.1002/jmri.20757. View

Kracht L, Miletic H, Busch S, Jacobs A, Voges J, Hoevels M . Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res. 2004; 10(21):7163-70. DOI: 10.1158/1078-0432.CCR-04-0262. View

Camelo-Piragua S, Kesari S . Further understanding of the pathology of glioma: implications for the clinic. Expert Rev Neurother. 2016; 16(9):1055-65. DOI: 10.1080/14737175.2016.1194755. View

10.

Pirotte B, Goldman S, Dewitte O, Massager N, Wikler D, Lefranc F . Integrated positron emission tomography and magnetic resonance imaging-guided resection of brain tumors: a report of 103 consecutive procedures. J Neurosurg. 2006; 104(2):238-53. DOI: 10.3171/jns.2006.104.2.238. View

11.

Verger A, Stoffels G, Bauer E, Lohmann P, Blau T, Fink G . Static and dynamic F-FET PET for the characterization of gliomas defined by IDH and 1p/19q status. Eur J Nucl Med Mol Imaging. 2017; 45(3):443-451. DOI: 10.1007/s00259-017-3846-6. View

12.

Okita Y, Nonaka M, Shofuda T, Kanematsu D, Yoshioka E, Kodama Y . (11)C-methinine uptake correlates with MGMT promoter methylation in nonenhancing gliomas. Clin Neurol Neurosurg. 2014; 125:212-6. DOI: 10.1016/j.clineuro.2014.08.004. View

13.

Kim S, Chung J, Im S, Jeong J, Lee D, Kim D . 11C-methionine PET as a prognostic marker in patients with glioma: comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2004; 32(1):52-9. DOI: 10.1007/s00259-004-1598-6. View

14.

Galldiks N, Verger A, Zaragori T, Unterrainer M, Suchorska B, Lohmann P . Comment on "Hypometabolic gliomas on FET-PET-is there an inverted U-curve for survival?". Neuro Oncol. 2019; 21(12):1612-1613. PMC: 6917398. DOI: 10.1093/neuonc/noz173. View

15.

Moulin-Romsee G, DHondt E, de Groot T, Goffin J, Sciot R, Mortelmans L . Non-invasive grading of brain tumours using dynamic amino acid PET imaging: does it work for 11C-methionine?. Eur J Nucl Med Mol Imaging. 2007; 34(12):2082-7. DOI: 10.1007/s00259-007-0557-4. View

16.

Nojiri T, Nariai T, Aoyagi M, Senda M, Ishii K, Ishiwata K . Contributions of biological tumor parameters to the incorporation rate of L: -[methyl-(11)C] methionine into astrocytomas and oligodendrogliomas. J Neurooncol. 2008; 93(2):233-41. DOI: 10.1007/s11060-008-9767-2. View

17.

Wijnenga M, French P, Dubbink H, Dinjens W, Atmodimedjo P, Kros J . The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis. Neuro Oncol. 2017; 20(1):103-112. PMC: 5761503. DOI: 10.1093/neuonc/nox176. View

18.

Metellus P, Colin C, Taieb D, Guedj E, Nanni-Metellus I, Maues de Paula A . IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients. J Neurooncol. 2011; 105(3):591-600. DOI: 10.1007/s11060-011-0625-2. View

19.

Ostrom Q, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J . CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol. 2014; 16 Suppl 4:iv1-63. PMC: 4193675. DOI: 10.1093/neuonc/nou223. View

20.

Appin C, Brat D . Biomarker-driven diagnosis of diffuse gliomas. Mol Aspects Med. 2015; 45:87-96. DOI: 10.1016/j.mam.2015.05.002. View